These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 12142046)

  • 1. Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma.
    Hogg RP; Honorio S; Martinez A; Agathanggelou A; Dallol A; Fullwood P; Weichselbaum R; Kuo MJ; Maher ER; Latif F
    Eur J Cancer; 2002 Aug; 38(12):1585-92. PubMed ID: 12142046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours.
    Agathanggelou A; Honorio S; Macartney DP; Martinez A; Dallol A; Rader J; Fullwood P; Chauhan A; Walker R; Shaw JA; Hosoe S; Lerman MI; Minna JD; Maher ER; Latif F
    Oncogene; 2001 Mar; 20(12):1509-18. PubMed ID: 11313894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. RASSF1A promoter region CpG island hypermethylation in phaeochromocytomas and neuroblastoma tumours.
    Astuti D; Agathanggelou A; Honorio S; Dallol A; Martinsson T; Kogner P; Cummins C; Neumann HP; Voutilainen R; Dahia P; Eng C; Maher ER; Latif F
    Oncogene; 2001 Nov; 20(51):7573-7. PubMed ID: 11709729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma.
    Tomizawa Y; Kohno T; Kondo H; Otsuka A; Nishioka M; Niki T; Yamada T; Maeshima A; Yoshimura K; Saito R; Minna JD; Yokota J
    Clin Cancer Res; 2002 Jul; 8(7):2362-8. PubMed ID: 12114441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
    Singh RB; Amare Kadam PS
    Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypermethylation of the tumor suppressor gene RASSFIA and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers.
    Yu MY; Tong JH; Chan PK; Lee TL; Chan MW; Chan AW; Lo KW; To KF
    Int J Cancer; 2003 Jun; 105(2):204-9. PubMed ID: 12673680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic inactivation of the candidate 3p21.3 suppressor gene BLU in human cancers.
    Agathanggelou A; Dallol A; Zöchbauer-Müller S; Morrissey C; Honorio S; Hesson L; Martinsson T; Fong KM; Kuo MJ; Yuen PW; Maher ER; Minna JD; Latif F
    Oncogene; 2003 Mar; 22(10):1580-8. PubMed ID: 12629521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer.
    Fullwood P; Marchini S; Rader JS; Martinez A; Macartney D; Broggini M; Morelli C; Barbanti-Brodano G; Maher ER; Latif F
    Cancer Res; 1999 Sep; 59(18):4662-7. PubMed ID: 10493522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 3p allele loss in early invasive breast cancer: detailed mapping and association with clinicopathological features.
    Martinez A; Walker RA; Shaw JA; Dearing SJ; Maher ER; Latif F
    Mol Pathol; 2001 Oct; 54(5):300-6. PubMed ID: 11577171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent epigenetic inactivation of chromosome 3p candidate tumor suppressor genes in gallbladder carcinoma.
    Riquelme E; Tang M; Baez S; Diaz A; Pruyas M; Wistuba II; Corvalan A
    Cancer Lett; 2007 May; 250(1):100-6. PubMed ID: 17084965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of chromosome 3p12-p21 tumour suppressor genes in clear cell renal cell carcinoma: analysis of VHL dependent and VHL independent pathways of tumorigenesis.
    Martinez A; Fullwood P; Kondo K; Kishida T; Yao M; Maher ER; Latif F
    Mol Pathol; 2000 Jun; 53(3):137-44. PubMed ID: 10897333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Editorial comment on 'Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma' by Hogg and colleagues.
    van den Brekel MW; Balm AJ
    Eur J Cancer; 2002 Aug; 38(12):1561-3. PubMed ID: 12142043
    [No Abstract]   [Full Text] [Related]  

  • 16. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.
    Wagner KJ; Cooper WN; Grundy RG; Caldwell G; Jones C; Wadey RB; Morton D; Schofield PN; Reik W; Latif F; Maher ER
    Oncogene; 2002 Oct; 21(47):7277-82. PubMed ID: 12370819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
    Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
    Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cells.
    Koutsimpelas D; Pongsapich W; Heinrich U; Mann S; Mann WJ; Brieger J
    Oncol Rep; 2012 Apr; 27(4):1135-41. PubMed ID: 22246327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
    Dammann R; Li C; Yoon JH; Chin PL; Bates S; Pfeifer GP
    Nat Genet; 2000 Jul; 25(3):315-9. PubMed ID: 10888881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant promoter hypermethylation and silencing of the critical 3p21 tumour suppressor gene, RASSF1A, in Chinese oesophageal squamous cell carcinoma.
    Wong ML; Tao Q; Fu L; Wong KY; Qiu GH; Law FB; Tin PC; Cheung WL; Lee PY; Tang JC; Tsao GS; Lam KY; Law S; Wong J; Srivastava G
    Int J Oncol; 2006 Mar; 28(3):767-73. PubMed ID: 16465383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.